Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ADC Therapeutics SA Common Shares
(NY:
ADCT
)
3.940
-0.020 (-0.51%)
Official Closing Price
Updated: 4:10 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ADC Therapeutics SA Common Shares
< Previous
1
2
3
4
5
6
7
8
9
Next >
ADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
July 20, 2022
From
ADC Therapeutics SA
Via
Business Wire
Overland ADCT BioPharma Announces First Patient Dosed in China with ZYNLONTA® in Combination with Rituximab in Global Phase 3 Clinical Trial
July 11, 2022
From
ADC Therapeutics SA
Via
Business Wire
Why ADC Therapeutics Shares Are Rising Today
↗
July 08, 2022
ADC Therapeutics SA (NYSE: ADCT) shares are trading higher by 11.56% to $10.23 Friday afternoon after the company entered into an exclusive license agreement with Swedish Orphan Biovitrum for the...
Via
Benzinga
The Daily Biotech Pulse: Pfizer Inks Pact With Africa For COVID-19 Pills, Emergent Bio & Ridgeback To Increase Access To Ebola Treatment, ADC Therapeutics & Sobi In European Pact For Lymphoma Drug
↗
July 08, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
ADC Therapeutics, Sobi Ink European Licensing Pact For Lymphoma Drug
↗
July 08, 2022
Via
Benzinga
Analyst Ratings for ADC Therapeutics
↗
May 10, 2022
Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter:
Via
Benzinga
ADC Therapeutics Announces Exclusive License Agreement with Sobi to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Europe and Select International Territories
July 08, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Appoints Jean-Pierre Bizzari, MD, to Board of Directors
July 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Other Anti-cancer Agents
June 29, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics: Q1 Earnings Insights
↗
May 09, 2022
ADC Therapeutics (NYSE:ADCT) reported its Q1 earnings results on Monday, May 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement.
Via
Benzinga
HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications
↗
June 13, 2022
Via
Benzinga
ADC Therapeutics Names David Gilman as Chief Business & Strategy Officer
June 13, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces Results from Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Cami) in Relapsed or Refractory Hodgkin Lymphoma
June 10, 2022
From
ADC Therapeutics
Via
Business Wire
ADC Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2022
From
ADC Therapeutics SA
Via
Business Wire
Stocks That Hit 52-Week Lows On Tuesday
↗
May 17, 2022
On Tuesday, 123 stocks made new 52-week lows.
Via
Benzinga
ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress
May 12, 2022
From
ADC Therapeutics SA
Via
Business Wire
RBC Capital Maintains Outperform Rating for ADC Therapeutics: Here's What You Need To Know
↗
May 10, 2022
RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the...
Via
Benzinga
Mid-Afternoon Market Update: Crude Oil Down 6%; Palantir Technologies Shares Slide
↗
May 09, 2022
U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 400 points on Monday.
Via
Benzinga
Mid-Day Market Update: Nasdaq Dips 450 Points; Hemisphere Media Group Shares Surge
↗
May 09, 2022
U.S. stocks extended losses midway through trading, with the Nasdaq Composite dropping around 450 points on Monday.
Via
Benzinga
90 Biggest Movers From Yesterday
↗
May 10, 2022
Gainers
Via
Benzinga
40 Stocks Moving In Monday's Mid-Day Session
↗
May 09, 2022
Gainers
Via
Benzinga
ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Announces CEO Transition
May 09, 2022
From
ADC Therapeutics SA
Via
Business Wire
Earnings Outlook For ADC Therapeutics
↗
May 06, 2022
ADC Therapeutics (NYSE:ADCT) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement. Analysts estimate that ADC...
Via
Benzinga
ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference
May 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
How To Attend ADC Therapeutics Q1 2022 Earnings Conference Call
↗
May 04, 2022
ADC Therapeutics (NYSE:ADCT) will host a conference call at 08:30 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend ADC Therapeutics (ADCT) Conference Call Follow this link to...
Via
Benzinga
ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022
May 03, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services
April 04, 2022
From
ADC Therapeutics SA
Via
Business Wire
ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021
March 17, 2022
From
ADC Therapeutics SA
Via
Business Wire
Cantor Fitzgerald Cuts ADC Therapeutics Price Target On 'Repositioned Zynlonta Pipeline Strategy'
↗
March 04, 2022
Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
